New drug ATH-097 enters first human safety trial
Knowledge-focused
Not yet recruiting
This Phase 1 trial will test the safety and tolerability of a single dose of ATH-097 in 44 healthy adults aged 18 to 55. Participants will be randomly assigned to receive either ATH-097 or a placebo, and researchers will monitor for side effects and measure how the drug is proces…
Phase: PHASE1 • Sponsor: Atheron Therapeutics, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC